The global myeloproliferative disorders treatment market is anticipated to record a significant CAGR over the forecast period, i.e., 2021-2029. The increasing investments in research and development activities along with rising incidences of myeloproliferative disorders is predicted to boost the market growth. Furthermore, the rising awareness for molecular abnormalities and cellular pathways associated with the MPN pathogenesis is expected to facilitate the development of clinical trials and novel drugs, which is estimated to boost the market growth. There is no known cure for this disorder, so the treatment is focused on treating the symptoms, which include weight loss, pale skin, blood clotting and excessive blood loss, splenomegaly, cachexia, and others. This raises the scope for R&D activities for developing novel drugs and treatment methods for this disorder, which is estimated to boost the market growth.
The market is segmented by type, treatment, and by end-user. Based on end-user, the market is segmented into hospitals, home care, specialty clinics, and others out of which hospital segment is anticipated to hold the largest market share throughout the forecast period. This can be attributed to growing healthcare facilities and a rising number of hospitals along with the increasing incidences of myeloproliferative disorders globally. Similarly, the segment for specialty clinics is also expected to grow at a significant rate over the forecast period as a result of the increasing number of specialized and disease-specific clinics which is estimated to boost the segment growth.
Based on the regional analysis, the global myeloproliferative disorders treatment market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. The market in the North America region is estimated to hold the largest market share in the market over the forecast period owing to the undergoing advanced research and development in the healthcare sector along with the presence of leading pharmaceutical companies conducting innovative clinical experiments. The market in the Europe region is projected to garner significant revenue during the forecast period owing to the development of novel treatment options, high demand for targeted therapies, and increasing geriatric population in the region. CLICK TO DOWNLOAD SAMPLE REPORT
The myeloproliferative disorders treatment market is further classified on the basis of region as follows:
Our in-depth analysis of the myeloproliferative disorder treatment market includes the following segments:
There is no known cure for the myeloproliferative disorder, however, there are various drugs and treatments to improve the symptoms and prolong the patient’s life. Major companies, developing these drugs, include, Incyte Corporation, Bristol-Myers Squibb Company, Novartis AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited and others.
FREQUENTLY ASKED QUESTIONS
Rising prevalence of myeloproliferative disorder due to overproduction of certain cells is estimated to drive the market growth.
The market is anticipated to attain a significant CAGR over the forecast period, i.e., 2021-2029.
Side effects of certain myeloproliferative disorder treatments are estimated to hamper the market growth.
The market in North America is estimated to show maximum business opportunities during the forecast period owing to the growing advanced medical research and development activities.
The major players in the market are Incyte Corporation, Bristol-Myers Squibb Company, Novartis AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited and others.
The company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.
The market is segmented by type, treatment, end-user, and by region.
The hospital segment is anticipated to hold largest market size over the forecast period owing to the increasing patient pool of myeloproliferative disorder.
Select License Type
Direct access to analyst to help you understand the market in a better way to handle your critical question
Citing your business specific requirement our consultant would assist you ensuring targeted goal is achieved
Get 10% free customization